Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763160 · ClinicalTrials.gov registry record · Phase 2
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
A Phase 2 study, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05763160 is a Phase 2 study that has completed, run by Raziel Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT05763160, a Phase 2 study, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label study in which subjects seeking further improvement of their SMF will be treated with a second treatment session of RZL-012. The second treatment session will be offered to subjects previously treated with RZL-012 under protocols RZL-012-SMF-SWMTG-P2US-001 or RZL-012-SMFC-P2US-001. Subjects who fully completed either of the trials and whose C-CAT score is 2, 3 or 4 will be eligible to participate in the new trial. For each subject, the study will consist of a screening period, baseline period in which subjects will receive a second treatment session of RZL-012 and a follow-up period. RZL-012 will be administered during a single treatment session via multiple injections into the submental area under the chin. Subjects will thereafter be monitored for safety and efficacy for at least 84 days.
Interventions
- DRUG RZL-012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-05-29 |
| Est. Completion | 2023-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05763160
The ClinicalTrials.gov registry entry for NCT05763160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raziel Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RZL-012 is the first listed.
NCT05763160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05763160 about?
NCT05763160 is a clinical study titled "An Open-label Study That Will Test a Second Treatment Session of RZL-012.". This is a Phase 2, open-label study in which subjects seeking further improvement of their SMF will be treated with a second treatment session of RZL-012. The second treatment session will be offered to subjects previously treated with RZL-012 under protocols RZL-012-SMF-SWMTG-P2US-001 or RZL-012-S...
What is the current status of trial NCT05763160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-05-29. Estimated completion is 2023-10-20.
What interventions are being tested in trial NCT05763160?
The interventions under investigation include: RZL-012 (DRUG).
Who is sponsoring clinical trial NCT05763160?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.